In This Section

Advocacy Detail

ASPET Applauds Passage of 21st Century Cures Act as Additional Investment in Biomedical Research

December 14, 2016

BETHESDA –The American Society for Pharmacology and Experimental Therapeutics (ASPET) commends legislators and President Obama for the final passage of the 21st Century Cures Act, which has now been signed into law.

We commend legislators for their bipartisan, bicameral support and vision in recognizing the critical importance of funding for medical research as a national priority. In particular, we are deeply grateful for the provision providing $4.8 billion over ten years in new funding for the National Institutes of Health (NIH) and $500 million for the Food and Drug Administration (FDA).

“The passage of this legislation is a victory for the biomedical research community, not just within the United States, but world-wide, and will have a significant impact on public health. We look forward to continued support from legislators in the appropriations process,” said Dr. David Sibley, ASPET President.

NIH’s contribution to the well-being and health of its citizens is a critical investment for the nation that will yield far greater returns through new discoveries and therapies.

With enhanced and sustained funding, NIH can continue to address the most promising scientific opportunities and critical healthcare needs of our country.

  • Statement
Last Updated: August 15, 2017

Job Postings